<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20220810160125+02'00'</creation_date><modification_date>D:20220810160125+02'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-3-22-2681_o_a_dec_0.pdf</pdf_file></head><body><section><header>en  
  en</header><p>european 
 commission</p><p>
 brussels, 10.8.2022</p><p>c(2022) 5911 final</p></section><section><header>commission implementing decision of 10.8.2022 
 relating to the designation of &quot;autologous human bone marrow-derived haematopoietic 
 and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes&quot; as 
 an orphan medicinal product under regulation (ec) no 141/2000 of the european 
 parliament and of the council</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decision of 10.8.2022 
 relating to the designation of &quot;autologous human bone marrow-derived haematopoietic 
 and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes&quot; as 
 an orphan medicinal product under regulation (ec) no 141/2000 of the european 
 parliament and of the council</header><p>(text with eea relevance) (only the dutch text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 141/2000 of the european parliament and of the 
 council of 16 december 1999 on orphan medicinal products
 1, and in particular the first sentence of article 5(8) thereof, 
 having regard to the application submitted by neuroplast b.v. on 20 may 2022 under article 
 5(1) of regulation (ec) no 141/2000, 
 having regard to the favourable opinion of the european medicines agency, drawn up on 14 
 july 2022 by the committee for orphan medicinal products and received by the commission 
 on 22 july 2022, 
 whereas: 
 (1) 
 the application submitted by neuroplast b.v. concerning the medicinal product 
 “autologous human bone marrow-derived haematopoietic and mesenchymal stem 
 cells depleted of erythrocytes, monocytes and lymphocytes” was validated on 14 june 
 2022 under article 5(4) of regulation (ec) no 141/2000. 
 (2) 
 &quot;autologous human bone marrow-derived haematopoietic and mesenchymal stem 
 cells depleted of erythrocytes, monocytes and lymphocytes&quot; meets the designation 
 criteria referred to in article 3(1) of regulation (ec) no 141/2000. 
 (3) 
 the application should therefore be accepted, 
 has adopted this decision: 
 article 1 the medicinal product “autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes” is designated 
 as an orphan medicinal product for the indication: treatment of frontotemporal dementia. it 
 shall be entered in the community register of orphan medicinal products under number 
 eu/3/22/2681.</p><p>
 1 oj l 18, 22.1.2000, p.1.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>article 2 the european medicines agency shall make available to all interested parties the opinion of the committee on orphan medicinal products referred to in this decision. 
 article 3 this decision is addressed to neuroplast b.v., urmonderbaan 22, geleen 6167 rd, limburg, nederland. 
 done at brussels, 10.8.2022</p><p>for the commission</p><p>
 sandra gallina</p><p>
 director-general</p></section></body></xml>